Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BUSINESS BITES: Zimmer becomes Zimmer Biomet; Amendia grows spine portfolio; Mindray MBO gathers pace

This article was originally published in Clinica

Executive Summary

Zimmer has finally completed its merger with Biomet, creating Zimmer Biomet, the world's second largest orthopedics company after Johnson & Johnson's DePuy Synthes. The closing comes 14 months after Zimmer and Biomet's private equity owners inked the cash-and-equity deal. At that time, the deal was valued at around $13.35bn. Zimmer’s stock price has since risen over the past year and the final figure for the deal is closer to $14bn. The announcement follows the news that it was offloading the US business of its unicompartmental high flex knee (ZUK) line to Smith & Nephew, for an undisclosed sum. The transaction was part of Zimmer’s efforts to appease US anti-trust authorities. Additionally, DJO Global said it had entered into an agreement to purchase the Biomet Cobalt bone cement, Optivac Cement Mixing Accessories and Discovery elbow system for the US market. Discovery will be DJO’s first elbow technology. That deal will close within the next 10 days, DJO said.

You may also be interested in...

'Open Payments' Peek: Device, DX Company Payments To Physicians Slightly Down In 2016

The latest updates to the US Open Payments database show spending by device and diagnostics firms on physician royalties, consulting fees, education, research and more was a bit less in 2016 compared to 2015, but still substantial. Top "general payment" spending came from Medtronic, Zimmer Biomet, Johnson & Johnson, Stryker, Smith & Nephew and Intuitive Surgical; while top "research payments" were reported by Edwards Lifesciences, Boston Scientific, and Abbott Laboratories, according to the CMS database.

Zimmer: Surprised By Biomet Quality Problems, But Responded Before FDA Arrived

Zimmer Biomet's response to a US FDA Form-483 says the firm was unaware of the quality systems woes at the targeted Biomet Warsaw, Ind., plant before its 2015 acquisition of the company. But, it emphasized, comprehensive fixes were in the works even before the 2016 agency inspection that generated more than a dozen substantive observations took place.

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts